Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study

BACKGROUND: Apatinib, a selective inhibitor of vascular endothelial growth factor receptor 2 (VEGFR 2), has exhibited modest antitumor efficacy in hepatocellular carcinoma (HCC). We aimed to evaluate the effectiveness and tolerability of apatinib versus sorafenib in patients with advanced HCC. METHO...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Transl Med
Main Authors: He, Wei, Liao, Leen, Hu, Dandan, Li, Binkui, Wang, Chenwei, Qiu, Jiliang, Liao, Yadi, Liu, Wenwu, Yang, Zhiwen, Zhang, Yuanping, Yuan, Yichuan, Li, Kai, Yuan, Yunfei, Zheng, Yun
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7475472/
https://ncbi.nlm.nih.gov/pubmed/32953800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-20-5298
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados